LIFITEGRAST Drug Patent Profile
✉ Email this page to a colleague
When do Lifitegrast patents expire, and when can generic versions of Lifitegrast launch?
Lifitegrast is a drug marketed by Eugia Pharma, Ingenus Pharms Llc, and Micro Labs. and is included in three NDAs.
The generic ingredient in LIFITEGRAST is lifitegrast. Three suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lifitegrast
A generic version of LIFITEGRAST was approved as lifitegrast by INGENUS PHARMS LLC on October 3rd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LIFITEGRAST?
- What are the global sales for LIFITEGRAST?
- What is Average Wholesale Price for LIFITEGRAST?
Summary for LIFITEGRAST
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 46 |
| Clinical Trials: | 18 |
| Patent Applications: | 259 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LIFITEGRAST |
| DailyMed Link: | LIFITEGRAST at DailyMed |
Recent Clinical Trials for LIFITEGRAST
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis Pharmaceuticals | Phase 4 |
| State University of New York College of Optometry | Phase 4 |
| University of Waterloo | Phase 4 |
Pharmacology for LIFITEGRAST
| Drug Class | Lymphocyte Function-Associated Antigen-1 Antagonist |
| Mechanism of Action | Lymphocyte Function-Associated Antigen-1 Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for LIFITEGRAST
Paragraph IV (Patent) Challenges for LIFITEGRAST
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| XIIDRA | Ophthalmic Solution | lifitegrast | 5% | 208073 | 4 | 2020-07-13 |
US Patents and Regulatory Information for LIFITEGRAST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eugia Pharma | LIFITEGRAST | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 215063-001 | Nov 7, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ingenus Pharms Llc | LIFITEGRAST | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 215058-001 | Oct 3, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Micro Labs | LIFITEGRAST | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 215081-001 | Aug 4, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
